Do antibodies to MBP, GFAP, amphiphysin, and tubulin reflect immune recognition of neural antigens?

Neural injury and altered blood–brain barrier (BBB) integrity can expose or permit immune access to CNS antigens, but a positive neural-antibody result is not, by itself, proof of pathogenic autoimmunity or a specific neurological disorder.

Clinical and longitudinal evidence

• Neural injury is followed by measurable autoreactivity in prospective traumatic spinal cord injury and traumatic brain injury cohorts. After severe TBI, anti-GFAP/GFAP-breakdown-product IgG increased approximately 3.77-fold from day 1 to days 7–10; greater rises correlated with worse 6-month function. Other cohorts found early IgM responses transitioning to IgG, with some antigen-specific responses persisting for months.
• Following stroke, a longitudinal cohort of 114 patients found that post-stroke infection—especially pneumonia—was associated with stronger 90-day Th1 responses to MBP and GFAP, demonstrating cellular as well as antibody-associated immune recognition.

Interpretation of antibody testing

• A confirmed antigen-specific antibody demonstrates immune binding to that antigen, but does not establish that it is injurious, intrathecally produced, or responsible for symptoms.
• Interpretation is highly antigen- and assay-dependent. CSF GFAPα-IgG with compatible inflammatory CNS features is more informative than isolated serum reactivity. In contrast, MBP and tubulin antibodies have substantial background reactivity. Commercial amphiphysin line-blot positives require confirmation, ideally with tissue-based or recombinant-antigen methods and paired serum/CSF testing.

BBB mechanisms

• BBB disruption plausibly facilitates CNS antigen–immune-system contact and entry of circulating antibodies. In rats, focal BBB opening allowed systemic anti-MOG antibody to enter the CNS and cause extensive complement-associated demyelination; antigen-specific T cells alone caused little demyelination.
• This supports BBB failure as a facilitator of effects from pre-existing antimyelin antibodies, not proof that it initiates antibody formation in humans.

Bottom line

• The claim is broadly credible: neural injury can be followed by immune recognition of MBP, GFAP, and related neural antigens, while BBB disruption is a biologically plausible contributor. Individual antibody results require rigorous analytical confirmation and clinical correlation.